Zytiga

Type: Product
Name: Zytiga
First reported 14 hours ago - Updated 12 hours ago - 1 reports

Why Johnson & Johnson's Patent Expiration Profile Is Fantastic

SummaryVery few firms have a more attractive investment profile than Johnson & Johnson. Johnson & Johnson boasts a cash-flow-derived Valuentum Dividend Cushion score of 2.2, and we don’t see us removing it from the Dividend Growth portfolio anytime soon. ... [Published Seeking Alpha - 14 hours ago]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Johnson & Johnson ( NYSE: JNJ     ) has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave ... [Published Motley Fool Discussion Boards - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Pharma driving J&J sales

Johnson & Johnson’s sales rose 3.5% year-on-year in the first quarter of 2014 to $18.1 billion, with net earnings of $4.7 billion.While sales in the consumer segment fell 3.2% to $3.5 billion, pharma grew 10.8% to $7.5 between January and March, overtaking ... [Published Pharmafocus - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

JNJ Beats Estimates, Device Sales Flat

The common stock of healthcare and medical device giant Johnson & Johnson (JNJ) soared to recent highs following the company's announcement of first quarter results that beat analysts' estimates.The company's robust performance was driven by new and existing ... [Published QMED - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Johnson and Johnson Earnings Surprises With Blockbuster Potential

By | More ArticlesEditor's Note: In the video below, Olysio's sales for the quarter are identified as $365 million. Olysio's actual sales were $354 million. The Fool regrets the error. A number of drugs contributed to this impressive growth, with revenue ... [Published Motley Fool - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 16 2014 - 1 reports

Johnson & Johnson Tops Street Views Amid Strong Drug Sales

Johnson & Johnson ( JNJ ) said Tuesday its first-quarter profit surged 35%, as sales growth in its pharmaceutical business helped the healthcare giant beat Wall Street expectations.The company also raised both ends of its full-year outlook by five cents, ... [Published FOXBusiness.com - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 16 2014 - 1 reports

Johnson & Johnson's Management Discusses Q1 2014 Results - Earnings Call Transcript

Johnson & Johnson ( JNJ ) Q1 2014 Results Earnings Conference Call April 15, 2014 8:30 AM ETOperatorGood morning and welcome to the Johnson & Johnson First Quarter 2014 Earnings Conference Call. All participants will be in a listen-only mode until the ... [Published Seeking Alpha - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

J&J 1Q net up 8 percent on sales jump

The world’s biggest maker of health-care products beat Wall Street expectations and raised its earnings outlook Tuesday. The maker of Band-Aids and biologic drugs said net income was $4.73 billion, or $1.64 per share, up from $3.5 billion, or $1.22 per ... [Published Northwest Herald - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

J&J hits one-week high as Q1 earnings beat, 2014 forecast boosted

3:52 pm by The company credited strong sales of new drugs: prostate cancer pill Zytiga ($512 million), hepatitis C medicine Olysio ($354 million) and Xarelto for preventing strokes ($319 million). Each is on pace to become blockbusters exceeding $1 billion ... [Published Proactive Investors USA - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast

Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson from trouncing analyst estimates Monday-or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, ... [Published FiercePharma - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Johnson & Johnson Increases Forecast as Profit Up on Drug Demand

Johnson & Johnson, the world’sbiggest maker of health-care products, said first-quarter profitrose 34 percent on demand for the company’s newest drugs. Thecompany raised its forecast for the year.Net income rose to $4.7 billion, or $1.64 a share, fro ... [Published Bloomberg - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Janssen's prostate cancer drug Zytiga now available in Trinidad & Tobago

The Chemistry , Food & Drugs Division of the Trinidad and Tobago Ministry of Health has approved Janssen's first orally administered androgen synthesis inhibitor ( testosterone ) medication 'Abiraterone Acetate' in the country for treatment of patients ... [Published BioPortfolio - Apr 15 2014]

Quotes

There it was in the words of Dominic Caruso, J&J's chief financial officer: "Despite the severe weather conditions, this was actually a very weak cold and flu season."
...is that the market believes that cabozantinib will have trouble competing against more established prostate cancer drugs like Johnson & Johnson "s Zytiga without strong evidence that the drug has a stellar efficacy profile. Indeed, the prostate cancercancer drug market has seen a number of newcomers of late, some of whom have struggled in this crowded space. That said, I believe Exelixis is now a bargain following this dramatic sell-off and is set to rebound. My thinking is simple: Some of the worst-selling prostate cancer drugs still see sales in the hundreds of millions and Exelixis" market cap has fallen to a mere $600 million...
"Given the company's strong financial position as demonstrated by its AAA debt rating, its strong cash flow generation and track record of consistently raising the dividend, we expect Johnson & Johnson to continue to grow the dividend in line with earnings, at a rate of 7 per cent per year, on average" Edward Jones analyst Judson Clark said in a note
...by successful new product launches and the continued growth of key products," said Alex Gorsky ( pictured ), chairman and chief executive, adding: "Our talented colleagues around the world continue to bring meaningful innovations to patients and customers, addressing significant unmet needs. We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results."

More Content

All (128) | News (121) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Drug sales bolster J&J's bottom line [The Phila... [Published BusinessWeek - 5 hours ago]
Why Johnson & Johnson's Patent Expiration Profi... [Published Seeking Alpha - 14 hours ago]
Motley Fool: April 19, 2014 [Published St Augustine Herald - Apr 19 2014]
1 of These 3 Cratering Biotechs is a Buy [Published Motley Fool Discussion Boards - Apr 18 2014]
How Big Is the Threat to This Johnson & Johnson... [Published Motley Fool Discussion Boards - Apr 18 2014]
Earnings Roundup: Johnson & Johnson Results Are... [Published Motley Fool - Apr 17 2014]
Pharma driving J&J sales [Published Pharmafocus - Apr 17 2014]
JNJ Beats Estimates, Device Sales Flat [Published QMED - Apr 16 2014]
Johnson and Johnson Earnings Surprises With Blo... [Published Motley Fool - Apr 16 2014]
4 keeper stocks to save your sanity [Published MSN Money - Apr 16 2014]
A prescription for a healthy dividend [Published GlobeAdvisor - Apr 16 2014]
Johnson & Johnson 1st-qtr 2014 results beat exp... [Published Pharma Letter - Apr 16 2014]
J&J 1Q net up 8 percent on sales jump [Published Northwest Herald - Apr 15 2014]
Johnson & Johnson's Earnings Report Impresses [Published Motley Fool Discussion Boards - Apr 15 2014]
J&J hits one-week high as Q1 earnings beat, 201... [Published Proactive Investors USA - Apr 15 2014]
Johnson & Johnson's Management Discusses Q1 201... [Published Seeking Alpha - Apr 15 2014]
Johnson and Johnson Beats Earnings And Revenues... [Published Bidness Etc - Apr 15 2014]
J&J’s Pharmaceutical Success Drives Increase in... [Published Washington Post - Apr 15 2014]
Here’s Why Johnson & Johnson Had a Crazy Good F... [Published Wall St. Cheat Sheet - Apr 15 2014]
J&J Q1 net up 8 percent on sales jump, lower costs [Published Investor's Business Daily - Apr 15 2014]
J&J Earnings Beat Estimates As Pharma Sales Shine [Published Investor's Business Daily - Apr 15 2014]
J&J beats forecasts as strong sales of new drug... [Published Sharenet - Apr 15 2014]
New drugs are J&J's Q1 heroes, spurring pharma ... [Published FiercePharma - Apr 15 2014]
3 Health Care Stocks Bucking the S&P Downtrend [Published Motley Fool Discussion Boards - Apr 15 2014]
Johnson & Johnson Tops Street Views Amid Strong... [Published FOXBusiness.com - Apr 15 2014]
Tuesday’s Top Health Care Stories: Johnson & Jo... [Published Motley Fool - Apr 15 2014]
Johnson & Johnson Lifts FY14 Earnings Forecast ... [Published RTTNews.com - Apr 15 2014]
Johnson & Johnson (JNJ) Beats Earnings Estimate... [Published Value Walk - Apr 15 2014]
Johnson & Johnson's sales increase 3.5% to $18.... [Published News-Medical.Net - Apr 15 2014]
Johnson & Johnson Increases Forecast as Profit ... [Published Bloomberg - Apr 15 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Here’s Why Johnson & Johnson Had a Crazy Good F... [Published Wall St. Cheat Sheet - Apr 15 2014]
Source: http://www.flickr.com/photos/59937401@N07/ Shares of  Johnson & Johnson  ( NYSE:JNJ ) jumped as much as 1.6 percent in early trading on Tuesday after the healthcare and pharmaceutical company reported strong first-quarter results . Sales ...
Trinidad & Tobago Ministry of Health approves J... [Published PBR - News - Apr 14 2014]
The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health has approved the introduction of Janssen's Abiraterone Acetate in the country for the treatment of patients with metastatic castration-resistant prostate cancer. ...
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
New York, NY, April 04, 2014 --( PR.com )-- The global biotechnology and pharmaceutical market have seen significant positive sentiments in the recent years, especially with innovation contributing to the availability of a range of new treatments for ...
Research and Markets: Therapeutic Class Overvie... [Published Business Wire Health News - Mar 27 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x36zgs/therapeutic_class) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of ...
Research and Markets: Global Prostate Cancer Th... [Published Business Wire Health News - Feb 14 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vhvpd8/prostate_cancer) has announced the addition of the "Global Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.